Congratulation on Rapafusyn Pharmaceuticals for raising $28 milllion successfully in its series A funding round. Rapafusyn Pharmaceuticals was awarded with Third Prize award in 2024 Biomedical Pitch Competition organized by Boston Chinese Investment Club （BCIC）and Hong Kong Science and Technology Parks Corporation (HKSTP)
https://bcicglobal.org/2024-biomedical-pitch-competition-winners/
the following was officially released news from AP
Rapafusyn Pharmaceuticals Secures $28 Million Series A to Advance Its Non-Degrading Molecular Glue Drug Discovery Platform
BY RAPAFUSYN PHARMACEUTICALS
Published 10:47 AM EDT, June 20, 2024
Rapafusyn’s RapaGlue™ platform rapidly discovers non-degrading molecular glues, a validated and highly sought-after modality to address challenging or previously undruggable disease targets
Financing led by 3E Bioventures Capital and Proxima Ventures Ltd. with participation from Lapam Capital
Founded by Professor Jun O. Liu of Johns Hopkins University School of Medicine, a pioneer in the molecular glue field